Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Chouaid C" with an ORCID

christos chouaid
No affiliation detected
218
Publications
7,368
Citations
View profile

Search results

1-25 of 412 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C, GFPC 08–2015 ENERGY investigators
Lancet Respir Med, S2213-2600(24)00264-9, 29 Oct 2024
Cited by: 0 articles | PMID: 39486424
Add to export list
Optimizing Treatment Strategies for <i>Egfr</i>-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights.
Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, Quantin X
Cancers (Basel), 16(21):3563, 23 Oct 2024
Cited by: 0 articles | PMID: 39518004 | PMCID: PMC11545234
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Impact of the COVID-19 pandemic on lung cancer diagnoses and mortality: A nationwide study in France.
Poucineau J, Khlat M, Lapidus N, Chouaïd C, Espagnacq M, Delory T, Le Cœur S
Cancer Epidemiol, 93:102679, 10 Oct 2024
Cited by: 0 articles | PMID: 39393189
Add to export list
Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report.
Naulleau G, Monnet I, Rousseau-Bussac G, Vinas F, Mangiapan G, Jabot L, Boudjemaa A, Chouaïd C, Auliac JB, Assié JB
Transl Lung Cancer Res, 13(9):2448-2452, 06 Sep 2024
Cited by: 0 articles | PMID: 39430317 | PMCID: PMC11484718
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Beyond lung cancer screening, an opportunity for early detection of chronic obstructive pulmonary disease and cardiovascular diseases.
Gendarme S, Maitre B, Hanash S, Pairon JC, Canoui-Poitrine F, Chouaïd C
JNCI Cancer Spectr, 8(5):pkae082, 01 Sep 2024
Cited by: 0 articles | PMID: 39270051 | PMCID: PMC11472859
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.
Cabart M, Mourey L, Pasquier D, Schneider S, Léna H, Girard N, Chouaid C, Schott R, Hiret S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Pérol M, Bosquet L, Cabarrou B
J Geriatr Oncol, 15(7):101819, 26 Jul 2024
Cited by: 0 articles | PMID: 39068144
Add to export list
[Compensation of occupational diseases during monitoring of the ARDCO cohort].
Gislard A, Gramond C, Clin B, Paris C, Delva F, Brochard P, Laurent F, Benoist J, Andujar P, Chouaïd C, Thaon I, Boudet L, Pairon JC
Rev Mal Respir, 41(7):472-487, 25 Jul 2024
Cited by: 0 articles | PMID: 39060158
Add to export list
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
Jacob M, Fournel P, Tissot C, Cadranel J, Bylicki O, Monnet I, Justeau G, Ricordel C, Thomas P, Falchero L, Locher C, Wislez M, Vergnenegre A, Abdiche S, Guisier F, Bizieux A, Lamy R, François G, De Chabot G, [...] Greillier L
Lung Cancer, 194:107868, 11 Jul 2024
Cited by: 0 articles | PMID: 39003937
Add to export list
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature.
Désage AL, Duruisseaux M, Lafitte C, Bayle-Bleuez S, Chouaid C, Fournel P, Pierret T
Cancer Treat Rev, 129:102805, 23 Jul 2024
Cited by: 0 articles | PMID: 39111188
Add to export list Review
Relationships between asbestos exposure and pleural plaques: dose and time effects using fractional polynomials.
Menant M, Benlala I, Thaon I, Andujar P, Julia B, Brochard P, Chouaid C, Clin B, Gislard A, Gramond C, Paris C, Pairon JC, Delva F
Occup Environ Med, 81(6):313-319, 10 Jul 2024
Cited by: 0 articles | PMID: 38925963 | PMCID: PMC11287532
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Amari L, Tomasini P, Dantony E, Rousseau-Bussac G, Ricordel C, Bigay-Game L, Arpin D, Morel H, Veillon R, Justeau G, Huchot E, Fournel P, Vergnenegre A, Bizeux A, Subtil F, Clarisse B, Decroisette C, Chouaid C, Greillier L, Bylicki O
Lung Cancer, 193:107843, 31 May 2024
Cited by: 0 articles | PMID: 38830303
Add to export list
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
Bylicki O, Guisier F, Scherpereel A, Daniel C, Swalduz A, Grolleau E, Bernardi M, Hominal S, Prevost JB, Pamart G, Marques MH, Cloarec N, Deshayes S, Raimbourg J, Veillon R, Oulkhouir Y, Audigier Valette C, Subtil F, Chouaïd C, [...] GFPC
Lung Cancer, 194:107866, 29 Jun 2024
Cited by: 0 articles | PMID: 38972083
Add to export list
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, [...] Girard N
ESMO Open, 9(6):103464, 03 Jun 2024
Cited by: 2 articles | PMID: 38833971 | PMCID: PMC11179087
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P
ESMO Open, 9(6):103473, 03 Jun 2024
Cited by: 0 articles | PMID: 38833966 | PMCID: PMC11179088
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.
Sanchis-Borja M, Guisier F, Swalduz A, Curcio H, Basse V, Maritaz C, Chouaid C, Auliac JB
Onco Targets Ther, 17:439-448, 29 May 2024
Cited by: 0 articles | PMID: 38836187 | PMCID: PMC11147782
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials.
Landre T, Assié JB, Chouahnia K, Des Guetz G, Auliac JB, Chouaïd C
Expert Rev Anticancer Ther, 24(8):775-780, 03 Jun 2024
Cited by: 1 article | PMID: 38813930
Add to export list Review
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.
Somme LB, Chouaid C, Moinard-Butot F, Barbe-Richaud JB, Greillier L, Schott R
BioDrugs, 38(4):487-497, 20 May 2024
Cited by: 0 articles | PMID: 38767823 | PMCID: PMC11247051
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.
Scotté F, Artru P, Saghatchian M, Chouaid C
Support Care Cancer, 32(6):347, 14 May 2024
Cited by: 0 articles | PMID: 38743147
Add to export list
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.
Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, Borget I
BioDrugs, 38(3):465-475, 20 Apr 2024
Cited by: 0 articles | PMID: 38643301
Add to export list
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
Nannini S, Guisier F, Curcio H, Ricordel C, Demontrond P, Abdallahoui S, Baloglu S, Greillier L, Chouaid C, Schott R
Curr Oncol, 31(3):1656-1666, 21 Mar 2024
Cited by: 0 articles | PMID: 38534959 | PMCID: PMC10969391
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Auliac JB, Thomas PA, Bylicki O, Guisier F, Curcio H, AlainVegnenègre, Swalduz A, Wislez M, Le Treut J, Decroisette C, Basse V, Falchero L, De Chabot G, Moreau D, Huchot E, Lupo Mansuet A, Blons H, Chouaïd C, Greillier L
Ther Adv Med Oncol, 16:17588359241236451, 06 Mar 2024
Cited by: 0 articles | PMID: 38455711 | PMCID: PMC10919127
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Lung cancer, comorbidities, and medication: the infernal trio.
Pluchart H, Chanoine S, Moro-Sibilot D, Chouaid C, Frey G, Villa J, Degano B, Giaj Levra M, Bedouch P, Toffart AC
Front Pharmacol, 14:1016976, 21 Feb 2024
Cited by: 0 articles | PMID: 38450055
Add to export list Review
Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis.
Landré T, Karaboué A, Buchwald ZS, Innominato PF, Qian DC, Assié JB, Chouaïd C, Lévi F, Duchemann B
ESMO Open, 9(2):102220, 16 Jan 2024
Cited by: 3 articles | PMID: 38232612
Add to export list
Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival.
Doubre H, Monnet I, Azarian R, Girard P, Meyer G, Trichereau J, Devillier P, Van Dreden P, Couderc LJ, Chouaid C, Vasse M
Res Pract Thromb Haemost, 8(2):102359, 01 Feb 2024
Cited by: 0 articles | PMID: 38666062 | PMCID: PMC11043639
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach.
Hagège M, Bringuier M, Martinez-Tapia C, Chouaïd C, Helissey C, Brain E, Lempdes GR, Dubot C, Bello-Roufai D, Geiss R, Kempf E, Gourden A, Elgharbi H, Garrigou S, Gregoire L, Derbez B, Canouï-Poitrine F
Age Ageing, 53(2):afae007, 01 Feb 2024
Cited by: 0 articles | PMID: 38346934 | PMCID: PMC10861365
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 412 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Chouaid C" with an ORCID

Search results

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.

Optimizing Treatment Strategies for <i>Egfr</i>-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights.

Impact of the COVID-19 pandemic on lung cancer diagnoses and mortality: A nationwide study in France.

Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report.

Beyond lung cancer screening, an opportunity for early detection of chronic obstructive pulmonary disease and cardiovascular diseases.

Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.

[Compensation of occupational diseases during monitoring of the ARDCO cohort].

A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).

Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature.

Relationships between asbestos exposure and pleural plaques: dose and time effects using fractional polynomials.

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).

Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.

Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.

First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials.

Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.

Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.

Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.

Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).

Lung cancer, comorbidities, and medication: the infernal trio.

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis.

Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival.

Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach.

Partnerships & funding

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Chouaid C" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:Chouaid C" with an ORCID